Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Rubius Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Rubius Therapeutics yıllık ortalama 8.6% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19.7% annual.

Anahtar bilgiler

8.6%

Kazanç büyüme oranı

11.0%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	n/a
Özkaynak getirisi	-1,187.4%
Net Marj	n/a
Son Kazanç Güncellemesi	31 Dec 2022

Yakın geçmiş performans güncellemeleri

Recent updates

Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?

Oct 28

Our Read On Rubius Therapeutics

Jul 11

Rubius Therapeutics EPS beats by $0.02

May 10

Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?

Feb 25

Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow

Jan 14

Rubius Therapeutics EPS misses by $0.01

Nov 09

Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers

Oct 28

Gelir ve Gider Dağılımı

Rubius Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OTCPK:RUBY Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Dec 22	-180	31	96
30 Sep 22	-215	44	135
30 Jun 22	-201	48	149
31 Mar 22	-207	52	152
31 Dec 21	-197	53	142
30 Sep 21	-182	53	127
30 Jun 21	-174	53	118
31 Mar 21	-162	51	108
31 Dec 20	-168	50	116
30 Sep 20	-172	51	121
30 Jun 20	-178	54	126
31 Mar 20	-179	56	128
31 Dec 19	-163	57	112
30 Sep 19	-146	55	98
30 Jun 19	-126	53	79
31 Mar 19	-107	48	63
31 Dec 18	-89	40	52
30 Sep 18	-80	38	42
30 Jun 18	-65	31	34
31 Mar 18	-54	26	27
31 Dec 17	-45	22	21

Kaliteli Kazançlar: RUBY şu anda kârlı değil.

Büyüyen Kar Marjı: RUBY şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: RUBY 'un son 5 yılda yıllık kazanç büyüme oranının pozitif olup olmadığını belirlemek için yeterli veri yok.

Büyüme Hızlandırma: RUBY 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: RUBY kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 0.5% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: RUBY hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -1187.4% ) sahiptir.

Rubius Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Rubius Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Rubius Therapeutics, Inc. to Report Q4, 2021 Results on Feb 25, 2022

Rubius Therapeutics, Inc. to Report Q4, 2020 Results on Feb 23, 2021

Rubius Therapeutics, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Rubius Therapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020

Recent updates

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

High number of new and inexperienced directors

Rubius Therapeutics, Inc. Announces Leadership Changes

Rubius Therapeutics, Inc. Announces Resignation of David Epstein as a Member of the Board

Rubius Therapeutics Announces Strategic Update

Price target increased to US$7.63

Rubius Therapeutics, Inc. Announces Resignation of Natalie Holles as Member of the Board of Directors

Price target increased to US$10.33

Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

Rubius Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Rubius Therapeutics, Inc. Appoints Susanne Schaffert to Its Board of Directors

Rubius Therapeutics, Inc.(NasdaqGS:RUBY) dropped from Russell 2000 Growth Index

Rubius: Poor Data, Punishing Environment, Beaten Stock

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Price target decreased to US$7.60

Price target decreased to US$8.67

Price target decreased to US$9.40

Price target increased to US$23.00

Rubius Therapeutics, Inc. Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

Rubius Therapeutics, Inc., Annual General Meeting, May 12, 2022

Rubius Looks Attractive Before AACR Data Readout

Price target increased to US$23.00

Rubius Therapeutics, Inc. to Report Q4, 2021 Results on Feb 25, 2022

Price target decreased to US$21.33

Price target decreased to US$23.33

Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

Price target decreased to US$25.67

Rubius Therapeutics to Highlight the Power of RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day

Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?

Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy

Our Read On Rubius Therapeutics

Rubius Therapeutics, Inc.(NasdaqGS:RUBY) dropped from Russell 3000E Value Index

Rubius Therapeutics, Inc. Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® in Ongoing Phase 1/2 Clinical Trial for Treatment of Advanced Solid Tumors

Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting

Forecast to breakeven in 2025

Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications

Rubius Therapeutics EPS beats by $0.02

Insider exercised options and sold US$313k worth of stock

Rubius Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

Rubius Therapeutics Announces Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240

New 90-day high: US$15.01

Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?

Price target raised to US$13.25

Executive Chairman notifies of intention to sell stock

Rubius Therapeutics, Inc. to Report Q4, 2020 Results on Feb 23, 2021

New 90-day high: US$10.00

Price target raised to US$10.29

Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow

Rubius Therapeutics, Inc. Provides an Operational Update

New 90-day high: US$8.83

New 90-day high: US$8.73

New 90-day high: US$5.92

Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic Clinical Oncology Program, Rtx-240, at the Society for Immunotherapy of Cancer’s Annual Meeting

Rubius Therapeutics EPS misses by $0.01

Rubius Therapeutics, Inc. Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240

Rubius Therapeutics, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers

New 90-day low: US$4.62

Rubius Therapeutics, Inc. Appoints Jose Carmona as Principal Financial Officer, Principal Accounting Officer and Treasurer Effective as of October 1, 2020

New 90-day low: US$4.75

New 90-day low - US$4.81

New 90-day low - US$4.85

Rubius Therapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020

New 90-day low - US$5.46

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi